What a bunch of BS. They have never said they are withholding TLD until they have an article published. That's a total fiction. Why would they do that? The whole point of TLD is to just give a quick snapshot of how the trial did and whether it successfully met the endpoints. Almost every biotech in the history of the world has released a TLD statement of some kind within a matter of days of data lock. That's a fact. Some of those announced success, and some of them announced failure. The one consistency among the small subgroup of companies that chose not to announce TLD is that they were all failures.
NWBO hasn't even told us what the endpoints are, much less provided TLD showing whether the trial met these endpoints. What you are stating as fact simply is not true. They have never said anything about holding TLD until they have a publication. Why? They have the data now. If the data is good, then why not release it? There is absolutely ZERO reason not to release positive data. This trial is a colossal disaster, and NWBO is circling the drain.
Market Data 
Markets 
AI
